Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
36.28 USD | +0.78% | +28.31% | +75.32% |
12:52pm | Oppenheimer Initiates Cartesian Therapeutics With Outperform Rating, $50 Price Target | MT |
May. 24 | Mizuho Securities Starts Cartesian Therapeutics With Buy Rating | MT |
Turnover - Change in analysts' estimates
Earnings Per Share (EPS) - Change in analysts' estimates
EBIT - Change in analysts' estimates
Cash or Net Debt - Change in analysts' estimates
Turnover
Earnings Per Share (EPS)
EBIT
Cash or Net Debt
- Stock Market
- Equities
- RNAC Stock
- Revisions Cartesian Therapeutics, Inc.